IVA Stock Analysis: Buy, Sell, or Hold?
IVA - Inventiva S.A. American Depository Shares
$5.91
-0.25 (-4.06%)
▼
5d:
-16.41%
30d:
+27.1%
90d:
+42.41%
WAIT
LOW Confidence
Last Updated: February 2, 2026
Earnings: Mar 25, 2026
Get Alerted When IVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IVA is down 16.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IVA is down 16.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IVA is currently trading at $5.91, which is considered fair relative to its 30-day fair value range of $4.80 to $6.66.
Technical Outlook: Technically, IVA is showing sideways momentum. The price is currently testing key support at $5.89. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.88 (+168.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IVA is showing sideways momentum. The price is currently testing key support at $5.89. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.88 (+168.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$4.80 -
$6.66
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 168.6% below Wall St target ($15.88)
- WARNING: Recommendation downgraded due to -16.4% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$4.80 -
$6.66
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$5.89
Resistance Level
$7.29
Current Trend
Sideways
Fundamental Context
Forward P/E (Next Year Est.)
-3.46
Wall Street Target
$15.88
(+168.6%)
Revenue Growth (YoY)
105.2%
Last updated: February 02, 2026 6:15 PM ET
Data refreshes hourly during market hours. Next update: 7:15 PM
Data refreshes hourly during market hours. Next update: 7:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 61 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
